Cognitive evolution in natalizumab-treated multiple sclerosis patients
Background: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. Objectives: […]
